Third Frontier Announces $38 Million in Research Commercialization Funding

Central Ohio Innovators Receive Nearly $15M for Biomedical and Engineering-Physical Sciences Projects

Ohio’s Third Frontier program has announced the awarding of more than $38 million to eight companies through the Ohio Research and Commercialization Program (RCP). Researchers and companies in Central Ohio were awarded $14.8 million. Those Central Ohio innovators receiving awards included

• Arteriocyte, Inc., a collaboration between OSU, University of Toledo and the Cleveland Clinic which was recommended for a biomedical award in the amount of $4.9 million to further develop stem cell-based therapeutics for use in treating cardiovascular disease and other conditions.

• Zyvex Performance Materials, Inc. along with a number of industry and university collaborators, which were recommended for an engineering and physical sciences RCP award in the amount of $4.9 million to further develop and produce carbon nanotubes to be used in the development of advanced composites for application in the marine, sporting goods, aerospace and high-end automotive industries. 

• Hyper Tech Research Inc., in collaboration with OSU, the Wright Center of Innovation in Biomedical imaging, RevWires and Siemens Magnet Technology, Ltd, recommended for $5 million to expand the use of Hyper Tech’s platform technology of high-field and high-temperature superconductor wire technology. 

For the full story and a complete list of RCP recipients, please see the release from the Ohio Department of Development:

http://development.ohio.gov/newsroom/releases/press.htm?id=3442